STEP trials
Semaglutide weight-management trial program. STEP 1 showed ~15% mean weight loss.
The STEP program established semaglutide 2.4mg (Wegovy) for weight management. STEP 1 showed about 15% mean body-weight reduction at 68 weeks versus 2.4% for placebo plus lifestyle.